Furiex Pharmaceuticals, Inc. (FURX) - NASDAQ
FURX is defunct.
  • Apr. 28, 2014, 12:48 PM
    | Apr. 28, 2014, 12:48 PM | 3 Comments
  • Apr. 28, 2014, 9:15 AM
    | Apr. 28, 2014, 9:15 AM
  • Apr. 28, 2014, 8:27 AM
    • Forest Labs (FRX) acquires Furiex Pharmaceuticals (FURX) for $95/share ($1.1B) in cash and up to $30/share in a Contingent Value Right (CVR) payable on the regulatory approval of eluxadoline.
    • Forest will divest Furiex's royalties on alogliptin and Priligy to Royalty Pharma for $415M which will reduce its purchase price by ~$315M (after tax).
    • Furiex shares are up 26% premarket on robust volume.
    | Apr. 28, 2014, 8:27 AM
  • Apr. 28, 2014, 7:58 AM
    • Forest Laboratories (FRX) has agreed to acquire Furiex Pharmaceuticals (FURX) for $1.1B in cash in a deal that Forest says will enable it to strengthen its position in Gastroenterology.
    • Forest, which is being bought by Actavis (ACT) is offering $95 a share vs Furiex's close of $80.15 on Friday.
    • Forest has also proposed up to $30 a share ($360M) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval
    • Forest has also agreed to sell Furiex's royalties on alogliptin and Priligy to Royalty Pharma for $415M once Forest has bought Furiex.
    • Furiex's shares are +28.51%. (PR)
    | Apr. 28, 2014, 7:58 AM | 2 Comments
  • Mar. 11, 2014, 5:41 PM
    • Top gainers, as of 5:15 p.m.: RTIX +26.3%. PAY +9.4%. RTRX +4.9%. AMC +4.3%. DMND +4.2%.
    • Top losers, as of 5:15 p.m.: MX -13.9%. KTOS -10.4%. FURX -6.7%. FCEL -6.4%. TEU -6.0%.
    | Mar. 11, 2014, 5:41 PM | 1 Comment
  • Feb. 27, 2014, 6:59 PM
    • When it comes to momentum stocks, Tesla is a pipsqueak compared to Intercept Pharmaceutics (ICPT), whose shares are +523% YTD, by far the top performing component in the Russell 2000; the second biggest gainer is Furiex Pharmaceuticals (FURX) up a piddling 132%.
    • Shares went parabolic in early January on positive news related to its liver-disease therapy and then came back to earth, but they have been climbing higher in recent weeks; ICPT retook $400 yesterday and the rally continued today, with the stock jumping another 5%.
    • ICPT has 45 employees and no products on the market, but its market cap is now ~$8.2B.
    | Feb. 27, 2014, 6:59 PM | 9 Comments
  • Feb. 19, 2014, 12:11 PM
    • Bloomberg reports Furiex Pharma (FURX +6.5%) has hired BofA/Merrill to help find a buyer. Shares have spiked higher in response.
    • Two weeks ago, Furiex more than doubled in response to news its Eluxadoline irritable bowel syndrome drug had met the company's main objectives in a late-stage study.
    | Feb. 19, 2014, 12:11 PM
  • Feb. 4, 2014, 3:51 PM
    • Ladenburg Thalmann hikes its price target for Furiex Pharmaceuticals (FURX +127.8%) to $137 from $57 after the drug developer's Eluxadoline experimental drug to treat a form of irritable bowel syndrome met main goals in a late-stage study.
    • Alogliptin, now approved in the U.S., Japan and Europe, represents another valuable asset, the firm says, expecting U.S. and E.U. revenues will start to impact the level of royalty revenues FURX receives during 2014; the company is entitled to tiered royalties of 8%-12% and 4%-8% in the U.S. and Europe/Japan, respectively (Briefing.com).
    • Mizuho does not consider positive data yesterday for FURX as a negative for Salix Pharma's (SLXP +2.5%) Xifaxan; a large population means room for two products, and different MOA and response rates mean variable patient responses, it says.
    | Feb. 4, 2014, 3:51 PM | 1 Comment
  • Feb. 4, 2014, 9:11 AM
    | Feb. 4, 2014, 9:11 AM | 2 Comments
  • Feb. 4, 2014, 7:43 AM
    • Furiex Pharmaceuticals' (FURX) Eluxadoline treatment for diarrhea-predominant irritable bowel syndrome (IBS-d) met the goals of two Phase III trials by improving stool consistency and relieving abdominal pain.
    • Furiex now plans to apply for FDA approval of Eluxadoline by the middle of the year and for EU authorization in early 2015.
    • IBS-d affects 28M people in the U.S. and major European markets. Furiex founder and chairman Fred Eshelman reckons the drug could bring in annual sales of $750M-$1B.
    • Eshelman has sparked buyout talk by saying that the company would launch the drug itself "if we don't get offers." However, the firm would have to raise money.
    • Shares +78%. (PR)
    | Feb. 4, 2014, 7:43 AM
  • Aug. 6, 2013, 4:17 PM
    • Furiex Pharmaceuticals (FURX): Q2 EPS of -$2.32 misses by $0.76.
    • Revenue of $3.0M misses by $8.94M. Shares +1.3% AH. (PR)
    | Aug. 6, 2013, 4:17 PM
  • Apr. 4, 2013, 3:03 PM

    Furiex Pharmaceuticals (FURX -1%) slips today, in spite of its earlier announcement of a $5M milestone payment from the Menarini Group for the launch of Priligy in France. The drug is currently marketed by FURX  in 16 countries in Europe, Asia and Latin America, and is approved in 56 countries worldwide.  Under the it's agreement with Menarini, FURX is eligible to receive up to $40M in sales-based milestones, plus tiered royalties ranging from the mid-teens to mid-twenties in percentage terms.

    | Apr. 4, 2013, 3:03 PM
  • Jan. 28, 2013, 12:45 PM
    Midday top 10 gainers: KERX +79%. FURX +51%. SHIP +39%. CTC +18%. HGSH +17%. SINO +14%. RSH +12%. CPBC +11%. OCZ +11%. ACAD +10%.
    Midday top 10 Losers: NVGN -61%. RPRX -27%. JOSB -18%. TRMD -16%. BYFC -15%. JVA -12%. DDD -11%. PRCP -10%. SSYS -9%. AKS -8%.
    | Jan. 28, 2013, 12:45 PM
  • Jan. 28, 2013, 9:10 AM
    Premarket gainers: FURX +49%. KERX +46%. NTE +14%. SNE +7%. DOLE +7%. HES +6%. GGC +6%. ACAD +5%.
    Losers: JOSB -17%. MTG -5%.
    | Jan. 28, 2013, 9:10 AM
  • Jan. 28, 2013, 8:11 AM

    Furiex Pharmaceuticals (FURX) extends its late Friday rally, moving up another 27.2% premarket on the strength of the news that the company could be in line for a milestone payment tied to a diabetes drug.

    | Jan. 28, 2013, 8:11 AM | 3 Comments
  • Jul. 27, 2012, 4:18 PM

    Furiex Pharmaceuticals (FURX +5.5%) ramped higher into the close after confirming that Takeda Pharmaceutical (TKPYY.PK) has resubmitted New Drug Applications to the FDA for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for treating adult type 2 diabetes. Under it's agreement with Takeda, FURX is eligible to receive a $25M milestone payment for the approval of the first of these two NDAs, as well as additonal royalties and sales-based milestones.

    | Jul. 27, 2012, 4:18 PM
Company Description
Furiex Pharmaceuticals, Inc. is a drug development collaborate company that collaborates with pharmaceutical and biotechnology companies to increase the value of their drug candidates by applying an accelerated approach to drug development.
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: United States